And they're off... Melanoma March 2016 begins!
29 February 2016
Melanoma March 2016 has kicked off with a bang! More than 300 people marched in Rockingham, WA and Devonport, TAS this weekend. It was great to see the melanoma community uniting to remember those who they have lost to melanoma, support those fighting the disease, and to raise money to support melanoma research.
Clinton Heal from MelanomaWA said of the Rockingham march “There were also many people there living with melanoma, and their family and friends were there to get behind them and the balloon release ceremony was a great way to both remember and rally together for all those touched by melanoma. With a large increase in participation compared to the 2015 event, we are excited for even bigger and better things for the 2017 Rockingham Melanoma March!”.
MIA’s Merrin Lavender attended the Devonport Melanoma March, which was the first march ever held in Tasmania. She said it was a great success and guest speakers include the founder of Melanoma TAS and the Deputy Premier of Tasmania, Jeremy Rockliff.
Thank you to everyone who came out to support Melanoma March and to our dedicated volunteers who have been tirelessly organsing these events.
This weekend marks just the beginning of a 6-week campaign for Melanoma March where Australia will unite against melanoma in 24 locations around the country. Register or make a donation to support Melanoma March today.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.